PMID- 36498632
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 11
IP  - 23
DP  - 2022 Nov 29
TI  - Nasal Symptoms in Asthmatic Patients under Treatment with Anti-IL-5 Monoclonal 
      Antibodies. A Real-Life Cohort Study.
LID - 10.3390/jcm11237056 [doi]
LID - 7056
AB  - Currently, some monoclonal antibodies (mAbs) are being studied for chronic 
      rhinosinusitis with nasal polyps (CRSwNP). Three anti-IL-5 mAb: mepolizumab, 
      reslizumab and benralizumab, have been tested through randomized clinical trials. 
      In this real-life study, we aimed to describe the nasal effects of a cohort of 
      asthmatic adults treated with anti-IL-5 mAb. Methods: We carried out an 
      observational study in adults (>/=18 years) on anti-IL-5 mAb treatment. Variables 
      included ACT and SNOT-22 questionnaires, nasal polyps score, blood total IgE 
      levels and blood eosinophil count. Results: Overall, 38 participants were 
      included in the study; 19 patients received mepolizumab, 17 were treated with 
      benralizumab and 2 patients were given reslizumab. There was a statistically 
      significant difference in the ACT and SNOT-22 scores before and after mAb 
      treatment. ACT score increased from 11.05 to 21.5 after treatment (p < 0.001). 
      SNOT-22 decreased from 57 to 37.3 after treatment (p = 0.004). No statistically 
      significant differences between mAb groups were observed regarding the ACT or the 
      SNOT-22 (p = 0.775) response (p = 0.775). In addition, 60.53% of patients 
      obtained a minimal clinically important difference (MCID) in SNOT-22. 
      Conclusions: A significant clinical response based on SNOT-22 score evolution 
      after anti-IL-5 mAb treatment was observed. This study also demonstrated that 
      blood eosinophil count, rather than serum total IgE levels, is the best predictor 
      of asthma symptom improvement, which was assessed through the ACT and SNOT-22 
      questionnaires.
FAU - Maza-Solano, Juan
AU  - Maza-Solano J
AUID- ORCID: 0000-0002-3588-9095
AD  - Rhinology Study Group, Young-Otolaryngologists of the International Federations 
      of Oto-Rhino-Laryngological Societies (YO-IFOS), 13005 Paris, France.
AD  - Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen 
      Macarena University Hospital, 41003 Sevilla, Spain.
FAU - Calvo-Henriquez, Christian
AU  - Calvo-Henriquez C
AD  - Rhinology Study Group, Young-Otolaryngologists of the International Federations 
      of Oto-Rhino-Laryngological Societies (YO-IFOS), 13005 Paris, France.
AD  - Service of Otolaryngology, Rhinology Unit, Hospital Complex of Santiago de 
      Compostela, 15706 Santiago de Compostela, Spain.
FAU - Alobid, Isam
AU  - Alobid I
AD  - Rhinology and Skull Base Unit, ENT Department, Hospital Clinic, Instituto de 
      Investigaciones Biomedicas August Pi i Sunyer (IDIBAPS), CIPERES, Barcelona 
      University, 08007 Barcelona, Spain.
FAU - Alvarez-Cendrero, Marta
AU  - Alvarez-Cendrero M
AD  - Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen 
      Macarena University Hospital, 41003 Sevilla, Spain.
FAU - Palomares, Oscar
AU  - Palomares O
AUID- ORCID: 0000-0003-4516-0369
AD  - Department of Biochemistry and Molecular Biology, School of Chemistry, 
      Complutense University of Madrid, 28040 Madrid, Spain.
FAU - Moreno-Luna, Ramon
AU  - Moreno-Luna R
AUID- ORCID: 0000-0003-0640-0550
AD  - Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen 
      Macarena University Hospital, 41003 Sevilla, Spain.
FAU - Santos-Perez, Jaime
AU  - Santos-Perez J
AUID- ORCID: 0000-0002-0423-9241
AD  - Service of Otolaryngology, Rhinology Unit, University Hospital of Valladolid, 
      47005 Valladolid, Spain.
FAU - Gonzalez-Garcia, Jaime
AU  - Gonzalez-Garcia J
AUID- ORCID: 0000-0002-5193-3869
AD  - Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen 
      Macarena University Hospital, 41003 Sevilla, Spain.
FAU - Sanchez-Gomez, Serafin
AU  - Sanchez-Gomez S
AUID- ORCID: 0000-0002-5897-7821
AD  - Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen 
      Macarena University Hospital, 41003 Sevilla, Spain.
LA  - eng
PT  - Journal Article
DEP - 20221129
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC9740481
OTO - NOTNLM
OT  - asthma
OT  - benralizumab
OT  - chronic rhinosinusitis
OT  - mepolizumab
OT  - nasal polyps
OT  - reslizumab
COIS- The authors declare no conflict of interest.
EDAT- 2022/12/12 06:00
MHDA- 2022/12/12 06:01
PMCR- 2022/11/29
CRDT- 2022/12/11 01:14
PHST- 2022/10/23 00:00 [received]
PHST- 2022/11/23 00:00 [revised]
PHST- 2022/11/25 00:00 [accepted]
PHST- 2022/12/11 01:14 [entrez]
PHST- 2022/12/12 06:00 [pubmed]
PHST- 2022/12/12 06:01 [medline]
PHST- 2022/11/29 00:00 [pmc-release]
AID - jcm11237056 [pii]
AID - jcm-11-07056 [pii]
AID - 10.3390/jcm11237056 [doi]
PST - epublish
SO  - J Clin Med. 2022 Nov 29;11(23):7056. doi: 10.3390/jcm11237056.